The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include a potential sale. Ananym said in a letter ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

Bio-Techne (TECH) rose 4% on a report that activist investor Ananym Capital Management has accumulated a stake in the maker of life-sciences tools and wants the company to pursue a strategic review, ...

German drugmaker Merck KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade, as it looks to strengthen its life sciences business.

Shares of U.S. life sciences company Bio-Techne (TECH) jumped more than +22% in premarket trading on Thursday after Merck KGaA (MKGAF) (MKKGY) agreed to acquire the company for $73 per share in cash, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The deal represents a 36% ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, ...

Germany’s Merck MRK-0.74%decrease; down pointing triangle KGaA said it struck a deal to buy U.S. life-sciences tools supplier Bio-Techne TECH-0.44%decrease; down pointing triangle for $11.3 billion, ...

Germany's Merck KGaA is poised to increase the size of its life sciences business, which provides tools for research, drug discovery, and manufacturing, with an $11.3 billion deal to acquire US rival ...